Malvern Panalytical, an England based company providing advanced analysis and services solutions for the pharma drug product development, as well as services and solutions for other industries, has completed the acquisition of Creoptix, a specialist
On January 11, 2022, UBS Group successfully completed its issuance of USD 1.5 bn in aggregate principal amount of Fixed Rate/Fixed Rate Senior Notes due February 2033 and USD 1.5 bn in aggregate principal amount of Fixed Rate/Fixed
Former International Olympic Committee (IOC) Director General Francois Carrard passed away in Lausanne on Sunday, January 9, 2022, at the age of 83, after a short illness. A Doctor of Law from the University of Lausanne, François
Bratschi has promoted Etienne Gard (pictured) to join the firm’s partnership. Etienne Gard’s legal practice focuses on corporate and contract law matters (especially domestic and cross-border m&a transactions) on the one
Borel & Barbey strengthens its corporate, banking and finance as well as its sports departments by promoting Pierre Turrettini and Alexandre Gallopin to partners of the firm as of 1 January 2022. Pierre Turrettini (pictured right) joined
Baker McKenzie advised NZZ (Neue Zürcher Zeitung) and Architonic ArchDaily, the online community for design and architecture, on the acquisition of international online magazine Designboom. Together, the two companies will form DAAily Platforms, provider
Standard Chartered has hired the World Bank’s legal leader Sandie Okoro (pictured) as its next general counsel, replacing David Fein who retired from the role at the end of 2021. Following his retirement, Fein joined
Occlutech Holding, a specialist provider of minimally invasive structural heart disease devices, addressing congenital heart defects, stroke prevention and heart failure, has successfully completed a private placement of Swedish Depositary Receipts (SDRs) worth SEK 450 million (
Start-up desk MLLStart! advised Clinical Research Ventures (CR Ventures), a global life-science investor with a focus on companies entering Phase I or II clinical trials based in Boston, USA, in its investment in Adiposs, a
Berner Kantonalbank has successfully completed the placement of CHF 200 m 0.85 per cent. Tier 2 bonds. Zürcher Kantonalbank acted as Structuring Advisor and Lead Manager and Berner Kantonalbank acted as Co-Manager. The bonds will be listed
